Vevoctadekin
- Generic Name
- Vevoctadekin
Simcha Therapeutics Launches Clinical Trials of ST-067 in Hematological Cancers
• Simcha Therapeutics initiates two clinical studies to evaluate ST-067, a decoy-resistant IL-18, in acute myeloid leukemia/myelodysplastic syndrome and multiple myeloma.
• The AML/MDS study (NCT06492707) will assess ST-067 in patients with persistent or recurrent disease post-hematopoietic cell transplantation.
• The multiple myeloma study (NCT06588660) will investigate ST-067 in combination with teclistamab to enhance T-cell fitness and persistence.
• Preclinical data supports ST-067's potential in hematologic cancers, with findings presented at the 2024 ASH Annual Meeting.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath